Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Initial Assessment of a Comprehensive Digital Smoking Cessation Program That Incorporates a Mobile App, Breath Sensor, and Coaching: Cohort Study.

Marler JD, Fujii CA, Utley DS, Tesfamariam LJ, Galanko JA, Patrick H.

JMIR Mhealth Uhealth. 2019 Feb 4;7(2):e12609. doi: 10.2196/12609.

2.

A Comprehensive Digital Program for Smoking Cessation: Assessing Feasibility in a Single-Group Cohort Study.

Patrick H, Fujii CA, Glaser DB, Utley DS, Marler JD.

JMIR Mhealth Uhealth. 2018 Dec 18;6(12):e11708. doi: 10.2196/11708.

3.

Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues.

Chen J, Falla TJ, Liu H, Hurst MA, Fujii CA, Mosca DA, Embree JR, Loury DJ, Radel PA, Cheng Chang C, Gu L, Fiddes JC.

Biopolymers. 2000;55(1):88-98.

PMID:
10931444
4.

IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis.

Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA, Falla TJ.

Antimicrob Agents Chemother. 2000 Jul;44(7):1803-8.

5.

Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity.

Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC, Loury DJ, Fiddes JC.

Antimicrob Agents Chemother. 1997 Aug;41(8):1738-42.

Supplemental Content

Loading ...
Support Center